Using oncolytic viruses to boost anti-tumor immunity
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
This study is looking at how a special virus can help your immune system fight advanced ovarian and colorectal cancers by boosting its ability to recognize and attack the cancer cells directly in the tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11058395 on NIH RePORTER |
What this research studies
This research investigates the use of oncolytic viruses, specifically Newcastle Disease Virus, to enhance the immune response against tumors. By administering these viruses directly into tumors, the goal is to stimulate the body's immune system to recognize and attack cancer cells more effectively. The study also explores how these viruses interact with immune cells and the tumor microenvironment, aiming to improve treatment outcomes for patients with advanced ovarian and colorectal cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced ovarian or colorectal cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage cancer or those who have not been diagnosed with ovarian or colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's own immune system to fight tumors.
How similar studies have performed: Previous studies have shown promise in using oncolytic viruses in cancer therapy, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Zamarin, Dmitriy — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zamarin, Dmitriy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.